title: ACS chemical neuroscience molecule spotlight on contrave.
abstract: Contrave is an investigational fixed-dose combination drug of naltrexone and bupropion currently in Phase III clinical trials for the treatment of obesity. Orexigen Therapeutics, Inc. has demonstrated efficacy of their product and is currently addressing FDA safety concerns and deciding future actions.
authors.affiliation: Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy , One University Park Drive, Nashville, Tennessee 37204, USA. susan.mercer@lipscomb.edu
authors.forename: Susan L
authors.initials: SL
authors.lastname: Mercer
mesh_terms: D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016642:Bupropion / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D004311:Double-Blind Method; D017277:Drug Approval; D004338:Drug Combinations; D006801:Humans; D009271:Naltrexone / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D009765:Obesity / Q000188:drug therapy*; D050177:Overweight / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D014481:United States; D014486:United States Food and Drug Administration; D015431:Weight Loss / Q000187:drug effects
chemical_list: D019440:Anti-Obesity Agents; D004338:Drug Combinations; C000591595:bupropion hydrochloride, naltrexone hydrochoride drug combination; D016642:Bupropion; D009271:Naltrexone